blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2359837

EP2359837 - Poly-tlr antagonist [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  19.04.2013
Database last updated on 03.10.2024
Most recent event   Tooltip19.04.2013Application deemed to be withdrawnpublished on 22.05.2013  [2013/21]
Applicant(s)For all designated states
Cadila Pharmaceuticals Ltd.
"Cadila Corporate Campus" Sarkhej-Dholka Road Bhat, Ahmedabad 382 210
GUJ / IN
[2011/34]
Inventor(s)01 / Modi, Indravaden Ambalal
Cadila Pharmaceuticals Limited "Cadila Corporate Campus" Sarkhej-Dholka Road Bhat
Ahmedabad Gujarat / IN
02 / Khamar, Bakulesh Mafatial
Cadila Pharmaceuticals Limited "Cadila Corporate Campus" Sarkhej-Dholka Road Bhat
Ahmedabad Gujarat / IN
 [2011/34]
Representative(s)Rigby, Barbara Nicole
Dehns
St Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[N/P]
Former [2011/34]Rigby, Barbara Nicole
Dehns St Bride's House 10 Salisbury Square
London EC4Y 8JD / GB
Application number, filing date11002055.921.11.2007
[2011/34]
Priority number, dateININ1931200623.11.2006         Original published format: IN IN19312006
[2011/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2359837
Date:24.08.2011
Language:EN
[2011/34]
Search report(s)(Supplementary) European search report - dispatched on:EP12.07.2011
ClassificationIPC:A61K35/74
[2011/34]
CPC:
C07K14/35 (EP,US); A61K35/74 (EP,GB,US); A61K39/04 (GB);
A61P1/04 (EP); A61P1/16 (EP); A61P11/00 (EP);
A61P11/08 (EP); A61P17/02 (EP); A61P25/00 (EP);
A61P25/28 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P31/04 (EP); A61P31/10 (EP); A61P31/12 (EP);
A61P33/06 (EP); A61P35/00 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61P9/04 (EP); A61P9/10 (EP);
Y02A50/30 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/44]
Former [2011/34]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Poly-TLR-Antagonist[2011/34]
English:Poly-tlr antagonist[2011/34]
French:Antagoniste poly-tlr[2011/34]
Examination procedure26.01.2012Examination requested  [2012/10]
20.02.2012Amendment by applicant (claims and/or description)
10.07.2012Communication of intention to grant the patent
21.11.2012Application deemed to be withdrawn, date of legal effect  [2013/21]
08.01.2013Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2013/21]
Parent application(s)   TooltipEP07825710.2  / EP2096914
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070825710) is  04.08.2010
Fees paidRenewal fee
11.03.2011Renewal fee patent year 03
11.03.2011Renewal fee patent year 04
28.11.2011Renewal fee patent year 05
21.11.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO03075827  (KHAMAR BAKULESH MAFATLAL [IN], et al);
 [E]WO2008114119  (CADILA PHARMACEUTICALS LTD [IN], et al);
by applicantUS5681824
 WO2004071465
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.